Aquestive Therapeutics (AQST) Shares Outstanding (2018 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Shares Outstanding (Entity) of $124.3 million for Q1 2026, up 25.14% year-over-year from $99.3 million in Q1 2025, and up 1.84% quarter-over-quarter from $122.0 million in Q4 2025.
Aquestive Therapeutics (AQST) Shares Outstanding (2018 - 2026) Analysis & Trends
Aquestive Therapeutics' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $124.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 25.14% year-over-year to $124.3 million; the TTM figure through Mar 2026 stood at $124.3 million (up 25.14% YoY), while the FY2025 annual figure was $122.0 million, up 33.51% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $124.3 million, up from $122.0 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $124.3 million in Q1 2026, with the low at $41.6 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $73.6 million (2024), against an average of $80.6 million.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) jumped 47.79% in 2024, then gained 9.11% in 2025.
- Aquestive Therapeutics' Shares Outstanding (Entity) stood at $54.8 million in 2022, then advanced by 25.0% to $68.5 million in 2023, then jumped by 33.39% to $91.4 million in 2024, then jumped by 33.51% to $122.0 million in 2025, then gained by 1.84% to $124.3 million in 2026.
- Business Quant data shows AQST's Shares Outstanding (Entity) at $124.3 million in Q1 2026, $122.0 million in Q4 2025, and $121.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 832.44 Mn |
| 10 | Aquestive Therapeutics | 554.35 Mn | 554.35 Mn | 9.80 Mn | 124.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.99 Mn |
| Mar 31, 2026 | 122.61 Mn |
| Dec 31, 2025 | 106.93 Mn |
| Sep 30, 2025 | 110.58 Mn |
| Jun 30, 2025 | 99.33 Mn |
| Mar 31, 2025 | 95.50 Mn |
| Dec 31, 2024 | 86.73 Mn |
| Sep 30, 2024 | 91.08 Mn |
| Jun 30, 2024 | 90.91 Mn |
| Mar 31, 2024 | 73.61 Mn |
| Dec 31, 2023 | 61.26 Mn |
| Sep 30, 2023 | 64.68 Mn |
| Jun 30, 2023 | 57.35 Mn |
| Mar 31, 2023 | 55.63 Mn |
| Dec 31, 2022 | 48.73 Mn |
| Sep 30, 2022 | 53.42 Mn |
| Jun 30, 2022 | 45.46 Mn |
| Mar 31, 2022 | 41.47 Mn |
| Dec 31, 2021 | 38.08 Mn |
| Sep 30, 2021 | 39.22 Mn |